Group 1 - The core point of the news is that Aibo Medical (688050.SH) announced a share reduction plan by shareholder Mao Liping, who intends to reduce his holdings by up to 1,934,000 shares, representing no more than 1% of the company's total share capital [1] - As of the announcement date, Mao Liping holds 5,604,413 shares, accounting for 2.90% of the total share capital, while together with his concerted actor Bai Ying, they hold a total of 11,304,459 shares, which is 5.85% of the total share capital [1] - Mao Liping's shares were acquired before the company's IPO and through capital reserve conversion after the listing, with these shares set to be tradable on July 31, 2023, and June 5, 2024, respectively [1] Group 2 - Aibo Medical's stock price hit a record low of 53.00 yuan during trading, marking the lowest price since its listing [2] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 29, 2020, with an issuance of 26.29 million shares at a price of 33.55 yuan per share, raising a total of 882 million yuan [2] - The net proceeds from the fundraising amounted to 804 million yuan after deducting issuance costs, which were 78.04 million yuan, with the lead underwriter being China Merchants Securities [2] Group 3 - The company issued 3,593,615 shares at a price of 79.20 yuan per share, raising a total of 284,614,308 yuan, with net proceeds of 280,612,310.30 yuan after deducting issuance costs [3] - The total amount raised from the two fundraising events is 1.167 billion yuan [4]

Core Viewpoint - Aibo Medical (688050.SH) announced the acquisition of 68.31% equity in Demai United (Chongqing) Medical Technology Co., Ltd. for a total consideration of RMB 683 million, which will enhance its position in the sports medicine sector and integrate Demai Medical as a subsidiary [1][2]. Group 1: Acquisition Details - The acquisition will be financed through a combination of merger loans and the company's own funds, with the transaction price set at RMB 68,300.46 million [1]. - Following the payment of the first installment, the equity transfer will be completed, granting Aibo Medical full rights as a shareholder of Demai Medical [1]. - Demai Medical is recognized as a leading enterprise in sports medicine in China, holding 276 patents and classified as a national high-tech enterprise [1]. Group 2: Valuation and Financials - A valuation report by Beijing Zhongfeng Asset Appraisal Co., Ltd. assessed Demai Medical's total equity value at RMB 107,429.74 million, with a net asset book value of RMB 24,234.48 million, resulting in an appraisal increment of RMB 83,195.26 million and a value increase rate of 343.29% [2]. - Key financial data for Demai Medical includes total assets of RMB 42,533.86 million and total liabilities of RMB 16,209.20 million as of December 31, 2025, with a projected net profit of RMB 3,501.67 million [3]. Group 3: Company Background - Aibo Medical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 29, 2020, raising a total of RMB 882 million, with a net amount of RMB 804 million after deducting issuance costs [4]. - The company plans to utilize the raised funds for expanding production capacity, developing high-end medical equipment, and enhancing its marketing network [4].